Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Medtronic
Moodys
AstraZeneca
Merck

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

APREPITANT Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Aprepitant, and when can generic versions of Aprepitant launch?

Aprepitant is a drug marketed by Glenmark Pharms Sa and Sandoz and is included in two NDAs.

The generic ingredient in APREPITANT is aprepitant. There are twenty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the aprepitant profile page.

US ANDA Litigation and Generic Entry Outlook for Aprepitant

  Start Trial

A generic version of APREPITANT was approved as aprepitant by SANDOZ on January 17th, 2020.

Drug patent expirations by year for APREPITANT
Drug Prices for APREPITANT

See drug prices for APREPITANT

Recent Clinical Trials for APREPITANT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Northwell HealthPhase 1/Phase 2
Ain Shams UniversityPhase 4
CR-CSSS Champlain-Charles-Le MoynePhase 3

See all APREPITANT clinical trials

Recent Litigation for APREPITANT

Identify potential future generic entrants

District Court Litigation
Case NameDate
Par Pharmaceutical, Inc. v. Twi Pharmaceuticals, Inc.2014-04-01
LUPIN ATLANTIS HOLDINGS S.A. v. APOTEX INC.2011-03-18
MERCK & CO., INC. v. SANDOZ INC.2009-02-27

See all APREPITANT litigation

Paragraph IV (Patent) Challenges for APREPITANT
Tradename Dosage Ingredient NDA Submissiondate
EMEND FOR SUSPENSION;ORAL aprepitant 207865 2016-11-23
EMEND CAPSULE;ORAL aprepitant 021549 2008-11-03

US Patents and Regulatory Information for APREPITANT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glenmark Pharms Sa APREPITANT aprepitant CAPSULE;ORAL 207777-001 Oct 12, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Sandoz APREPITANT aprepitant CAPSULE;ORAL 090999-001 Sep 24, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
Glenmark Pharms Sa APREPITANT aprepitant CAPSULE;ORAL 207777-002 Oct 12, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Glenmark Pharms Sa APREPITANT aprepitant CAPSULE;ORAL 207777-003 Oct 12, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Sandoz APREPITANT aprepitant CAPSULE;ORAL 090999-003 Sep 24, 2012 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
McKinsey
Moodys
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.